ABSTRACT
Introduction: Hypereosinophilic syndrome (HES) and immune thrombocytopenic purpura (ITP) have been reported to co-occur with ulcerative colitis (UC). However, the exact pathogenic mechanisms of their occurrence remain elusive. In this article, we aim to describe two cases of UC patients who developed refractory HES and ITP and elaborate on their potential pathogenesis. Case Study: We report two middle-aged patients diagnosed with UC. The first patient developed HES that was refractory to conventional medical therapy of idiopathic HES, and the second developed refractory ITP that failed steroid and immunosuppressive therapy. Both conditions improved considerably following colectomy, suggesting they are of a reactive rather than idiopathic nature. Conclusion: In patients with UC and refractory comorbid HES or ITP, the reactive nature of these comorbidities should be taken into consideration, and colectomy, therefore, should be considered if clinically indicated.
ABSTRACT
BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to assess the feasibility of bendamustine as an alternative to BCNU. We compared 71 patients who received either bendamustine (Benda-EAM group) or BCNU (BEAM group) conditioning. Considering previous reports of increased cardiotoxicity, nephrotoxicity, and mucositis, we adopted a lower bendamustine dose of 160 mg/m2/day administered for 2 days. There was no increase in nephrotoxicity and cardiotoxicity. Further, positive results were also obtained for neutrophil and platelet engraftment, appearing earlier in patients treated with Benda-EAM (10 vs. 14 days and 16 vs. 27 days, respectively). However, caution is warranted because an increased frequency of Grade 3 mucositis was observed in the Benda-EAM group (82.4% vs. 48%). This was accompanied by an increased need for parenteral nutrition. Despite the lower dose of bendamustine, the overall and progression-free survival rates were comparable between the Benda-EAM and BEAM groups. In conclusion, a lower dose of bendamustine may be an attractive alternative to BCNU as a tolerable treatment modality for patients with relapsed/refractory lymphoma.
Subject(s)
Hematopoietic Stem Cell Transplantation , Lymphoma , Bendamustine Hydrochloride , Cardiotoxicity , Carmustine , Humans , Lymphoma/drug therapy , Mucositis/chemically induced , Retrospective Studies , Transplantation, AutologousABSTRACT
PURPOSE: The study assessed the effectiveness of a site-specific video educational material in improving patient understanding and confidence regarding radiation therapy trajectory. METHODS AND MATERIALS: A quasi experimental longitudinal pretest posttest study was conducted at a referral radiation therapy center from May 2020 to September 2020. It included 52 adult patients admitted for a first course radical radiation therapy. One generic and 6 site-specific (breast, pelvis, head and neck, brain, chest and abdomen, and bladder) animated cartoon videos were developed in house to provide concise overview of the overall patient's trajectory in radiation therapy, with full visual description of the procedures and specific preparation measures. A 14-item questionnaire was designed to assess pre- and postintervention levels of understanding and confidence of patients, with calculation of and an understanding and confidence score (UCS), range 0-14. RESULTS: The mean (standard deviation) UCS in pre- and postintervention was 9.36 (2.48) and 11.92 (1.34) out of 14, respectively, indicating a mean increase of 2.57 subsequent to the intervention (P < .001). The effect size was large with a Cohen's d = 1.01. Of the 14 dimensions explored, 8 were observed to have remarkable improvement, notably understanding the purpose of the tattoo mark, reason of daily or weekly imaging, and what to expect with radiation therapy. Participants with poor reading ability had greater increase in UCS (ΔUCS = 4.25 vs ≤2.33) and in 5 out of 8 dimensions with remarkable improvement. CONCLUSIONS: The use of digital educational material in radiation oncology meets the urgent need for providing patients with concise and site-specific information, while sparing extra hospital visits to meet education coordinators during the COVID-19 crisis. Additional studies are warranted to assess both the clinical and long-term effectiveness of the educational material, using a longitudinal controlled design.
ABSTRACT
Aplastic anemia is a relatively rare but potentially fatal disorder, with a reported higher incidence in developing countries in comparison to the West. There are significant variations in epidemiological as well as etiological factors of bone marrow failure syndromes in the developing countries in comparison to the developed world. Furthermore, the management of bone marrow failure syndromes in resource constraint settings has significant challenges including delayed diagnosis and referral, limited accessibility to healthcare facilities, treatment modalities as well as limitations related to patients who require allogeneic stem cell transplantation. Here we will provide a review of the available evidence related to specific issues of aplastic anemia in the developing countries and we summarize suggested recommendations from the Eastern Mediterranean blood and bone marrow transplantation (EMBMT) group and the severe aplastic anemia working party of the European Society of blood and marrow transplantation (SAAWP of EBMT) related to the diagnosis and therapeutic options in countries with restricted resources.
Subject(s)
Anemia, Aplastic , Hematopoietic Stem Cell Transplantation , Anemia, Aplastic/diagnosis , Anemia, Aplastic/therapy , Bone Marrow , Bone Marrow Failure Disorders , Bone Marrow Transplantation , Humans , Transplantation ConditioningABSTRACT
Saudi Arabia is the largest of the Arabian Gulf countries with a total population of 33.41 million as of 2017. This report summarizes the experience from four leading tertiary care hematopoietic stem cell transplantation (HSCT) centers in Saudi Arabia representing more than 90% of all HSCTs performed in the country. Between 1984 and 2016, a total of 6,184 HSCTs were performed. Of these, 3,586 HSCTs were performed in adults and 2,598 HSCTs were performed in pediatric patients. Malignancy was the main indication for transplantation (47%). While most transplants were performed from an identical sibling donor, HSCTs from cord blood, unrelated and, more recently, haploidentical donors have also been performed. Relative shortage of HSCT bed capacity is perceived to be a limiting factor in Saudi Arabia. Lately, more HSCT centers are emerging with rapid growth, which may significantly improve the access to HSCT in the country in the near future.